IDH1 and glioblastoma: The current DC-vaccination trial included 37 patients with a diagnosis of recurrent glioblastoma (IDH-1 wild type, n = 28, 76%) or grade 4 astrocytoma (IDH-1 mutated, n = 9, 24%).